Wedbush maintains Denali Therapeutics at Outperform, raises price target to $24 from $23

Denali Therapeutics (DNLI) reported Q3 2026 revenue of $17.8M, exceeding guidance, and raised Q4 outlook to $30-32M. Growth was driven by payer coverage and patient transitions. The company expects a permanent J-Code to aid Q4 revenue. CEO Ryan Watts discussed regulatory paths for FTD and Pompe programs, and CFO Alexander Schuth mentioned $1B in cash for advancements. AVLAYAH's price is $5,200 per vial, with no reported discontinuations.

Denali Therapeutics (DNLI) stock rose 7.9% in pre-market trading after Q3 2026 earnings beat estimates, with revenue of $17.77M and EPS of $0.37. AVLAYAH, its therapy for neurologic Hunter syndrome, drove growth, with revenue up 394% QoQ. Management guided Q4 revenue to $30M-$32M. Analysts raised price targets, with a consensus of $35.85. U.S. equity futures also rallied post-election.

Denali Therapeutics reported Q3 revenue growth due to expanded coverage and patient transitions. AVLAYAH's J-code became effective, simplifying billing. Revenue is expected to rise steadily. Sanfilippo syndrome type A trial data to be presented in 2027. Alzheimer's programs in clinical trials. Q3 net income was $70.1M, with $1.01B in cash. Company aims to build two commercial brands and advance multiple programs by 2028.

Denali Therapeutics (DNLI) reported Q3 earnings beating estimates, with adjusted EPS of $0.37 vs. -$0.37 expected. Revenue was $17.77M, surpassing the $12.22M estimate. AVLAYAH sales drove growth, with net product revenue of $17.8M. The company guided Q4 2026 net product revenue to $30.0M-$32.0M. DNLI shares rose 9.8% in after-hours trading.

Denali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights • AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter • Continued growth expectations drive Q4 2026 net produ

Denali Therapeutics (DNLI) announced its drug AVLAYAH (tividenofusp alfa-eknm) won the 2026 Prix Galien USA Best Biotechnology Product. AVLAYAH, FDA-approved in March 2026, treats Hunter syndrome by crossing the blood-brain barrier. The company's stock is trading at $18.86, down 2.35%.